Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Germany struggles to shift AstraZeneca vaccine doses

Thu, 25th Mar 2021 16:19

* Germany has administered just 60% of delivered AZ
doses-RKI data

* Merkel says "not ok" if vaccination appointments going
unused

* Scepticism, patchy state rollout, data monitoring play a
role

By Caroline Copley

BERLIN, March 25 (Reuters) - Berlin pensioner Gerhard
Schaeufele decided he'd prefer to wait 10 days and cross the
city for a shot of the BioNTech/Pfizer
coronavirus vaccine, rather than accept an AstraZeneca vaccine
in two days' time at his local centre.

"A week ago, maybe I would have taken AstraZeneca," the
72-year-old retired university arts teacher told Reuters,
describing himself as someone who follows his gut feeling.

But he said the recent back-and-forth over the vaccine's
efficacy and safety put him off.

AstraZeneca says its vaccine is safe and effective, citing
extensive trial data. Millions of doses have been safely
administered around the world and the EU's medicines watchdog
and the World Health Organisation have reaffirmed it safe. Most
of the states which briefly halted its use, including Germany,
have resumed giving the shot.

However, Schaeufele's hesitancy towards AstraZeneca's shot
underscores the challenge Berlin faces as it seeks to ramp up
its sluggish vaccine rollout while contending with a third wave
of the pandemic, driven by more infectious virus variants.

It's an issue faced by governments across the European Union
as they seek to get their vaccine rollouts back on track. A
third of Danes say they won't accept the Anglo-Swedish shot,
while some in France remain sceptical.

According to data from the Robert Koch Institute (RKI) of
infectious diseases, around 2.1 million or 60 percent of the
doses of AstraZeneca's vaccine to arrive in Germany have been
used. By comparison 83% of BioNTech/Pfizer vaccines have been
used.

A survey of Germany's states, who are responsible for the
vaccine rollout, suggests the low take-up is attributable in
part to organisational bottlenecks as well as people's
uncertainty over the AstraZeneca vaccine.

Chancellor Angela Merkel, 66, who is facing growing
criticism over her handling of the pandemic, has said she would
herself accept the AstraZeneca vaccine when her turn came.

She told the Bundestag on Thursday that it was "not ok" that
appointments were going unused.

In Berlin, the AstraZeneca shot is available at former
airports Tegel and Tempelhof, and appointments were available to
those eligible as soon as this coming weekend when Reuters
checked on Thursday.

At Berlin's four other centres, which administer BioNTech
and Moderna, no time slots were available within the
next month.

BUREAUCRATIC BACKLOGS

In Bremen, the country's smallest state, 80% of its
AstraZeneca doses have been administered with local officials
saying they were quick to offer appointments to teachers and
daycare staff once the priority list was amended on Feb. 24.

In Saxony by contrast, less than 30% of its AstraZeneca
doses have so far been used. The state has not yet made the
vaccine available in hospitals although medical staff would be
eligible, according to a person working on the rollout.

A spokeswoman for the health ministry in the state of
Saxony-Anhalt said the initial recommendation that the
AstraZeneca shot only be given to those under 65 had acted as a
hindrance, citing "greater organisational effort" to arrange
appointments for those in the next priority group.

Meanwhile, in Mecklenburg-Vorpommern, shots were delayed
after 12,200 AZ doses had to be put in "quarantine" for a week
due to an error in the cold chain of the delivery company.

One of the biggest hurdles for the rollout has been
inconsistent deliveries and supply constraints. But this is set
to change with deliveries of around 15 million doses in total of
all three approved vaccines in April.

Ruth Waldmann, health spokesperson for the Social Democrats
in the Bavarian state parliament, said it was time to "fire up
the vaccination turbo" by bringing on board family doctors.

Germany plans to supply doctors with a million vaccines per
week from April rising to three million by the end of the month,
and hopes this will add more firepower and flexibility to its
rollout.

Family doctors could easily inoculate 2.5 million people per
week if each practice does just 10 shots per day, according to
the national association.
(Reporting by Caroline Copley
Additional reporting by Michael Nienaber, Thomas Escritt and
Christina Amann
Editing by Alexandra Hudson)

More News
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.